346 related articles for article (PubMed ID: 9744556)
1. Kinetic analysis in living cells of the inhibition of the P-glycoprotein-mediated efflux of anthracyclines by vinca alkaloids.
Pereira E; Tarasiuk J; Garnier-Suillerot A
Chem Biol Interact; 1998 Jul; 114(1-2):61-76. PubMed ID: 9744556
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
[TBL] [Abstract][Full Text] [Related]
3. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
4. Vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.
Etievant C; Barret JM; Kruczynski A; Perrin D; Hill BT
Invest New Drugs; 1998; 16(1):3-17. PubMed ID: 9740539
[TBL] [Abstract][Full Text] [Related]
5. Mobile ionophores are a novel class of P-glycoprotein inhibitors. The effects of ionophores on 4'-O-tetrahydropyranyl-adriamycin incorporation in K562 drug-resistant cells.
Borrel MN; Pereira E; Fiallo M; Garnier-Suillerot A
Eur J Biochem; 1994 Jul; 223(1):125-33. PubMed ID: 7518390
[TBL] [Abstract][Full Text] [Related]
6. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).
Adams DJ; Knick VC
Invest New Drugs; 1995; 13(1):13-21. PubMed ID: 7499103
[TBL] [Abstract][Full Text] [Related]
8. Partial inhibition of the P-glycoprotein-mediated transport of anthracyclines in viable resistant K562 cells after irradiation in the presence of a verapamil analogue.
Mankhetkorn S; Teodori E; Garnier-Suillerot A
Chem Biol Interact; 1999 Jul; 121(2):125-40. PubMed ID: 10418960
[TBL] [Abstract][Full Text] [Related]
9. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
10. Experimental in vivo cross-resistance of vinca alkaloid drugs.
Maral R; Bourut C; Chenu E; Mathe G
Cancer Chemother Pharmacol; 1981; 5(3):197-9. PubMed ID: 7296754
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents.
Pauwels O; Kiss R; Pasteels JL; Atassi G
J Pharm Pharmacol; 1995 Oct; 47(10):870-5. PubMed ID: 8583358
[TBL] [Abstract][Full Text] [Related]
12. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacology of Catharanthus alkaloids].
Levêque D; Wihlm J; Jehl F
Bull Cancer; 1996 Mar; 83(3):176-86. PubMed ID: 8695919
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines.
Tolis C; Photiou A; Camplejohn RS; Retsas S
Anticancer Res; 1993; 13(1):161-6. PubMed ID: 8476208
[TBL] [Abstract][Full Text] [Related]
15. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
16. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.
Zhang Y; Yang SH; Guo XL
Biomed Pharmacother; 2017 Dec; 96():659-666. PubMed ID: 29035832
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine.
Ngan VK; Bellman K; Hill BT; Wilson L; Jordan MA
Mol Pharmacol; 2001 Jul; 60(1):225-32. PubMed ID: 11408618
[TBL] [Abstract][Full Text] [Related]
18. Saturable function of P-glycoprotein as a drug-efflux pump in multidrug-resistant tumour cells.
Miyamoto KI; Koga-Takeda K; Koga K; Ohshima T; Nomura M
J Pharm Pharmacol; 1996 May; 48(5):522-5. PubMed ID: 8799879
[TBL] [Abstract][Full Text] [Related]
19. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
20. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]